Castle Biosciences CSTL Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $344.23M+3.7% | $332.07M+51.1% | $219.79M+60.4% | $137.04M+45.7% | ||
| $71.03M+18.0% | $60.21M+33.8% | $44.98M+40.5% | $32.01M+102% | ||
| $51.85M-0.4% | $52.04M-2.9% | $53.62M+19.4% | $44.9M+51.5% | ||
| $229.32M+14.6% | $200.05M+11.0% | $180.15M+26.0% | $143M+64.9% | ||
| -$42.81M-594% | $8.67M+113% | -$67.98M+6.7% | -$72.86M-81.8% | ||
| -12.4%-15.0pp | 2.6%+33.5pp | -30.9%+22.2pp | -53.2%-10.6pp | ||
| $86K-85.1% | $577K+5,145% | $11K-35.3% | $17K+1,600% | ||
| $144K— | —— | $0— | —— | ||
| -$5.36M— | —— | $101K+106% | -$1.82M+79.1% | ||
| -$24.16M-232% | $18.25M+132% | -$57.47M+14.4% | -$67.14M-115% | ||
| -7%-12.5pp | 5.5%+31.6pp | -26.1%+22.8pp | -49%-15.7pp | ||
| -$0.84-235% | $0.62+129% | -$2.15+17.0% | -$2.59-109% | ||
| -$2.04M-108% | $24.67M+144% | -$55.65M+10.7% | -$62.31M-69.9% | ||
| -0.6%-8.0pp | 7.4%+32.7pp | -25.3%+20.2pp | -45.5%-6.5pp | ||
| -$42.81M-594% | $8.67M+113% | -$67.98M+6.7% | -$72.86M-81.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Castle Biosciences's revenue?
- Castle Biosciences (CSTL) generated $339.9M in revenue over the trailing twelve months, down 2.1% year over year.
- Is Castle Biosciences profitable?
- Castle Biosciences is not currently profitable: it reported a net loss of $12.8M over the trailing twelve months, a -3.8% net margin.
- What are Castle Biosciences's profit margins?
- Gross margin is 77.9% and operating margin is -9.8%, with a -3.8% net margin.
- What is Castle Biosciences's earnings per share?
- Castle Biosciences's diluted EPS over the trailing twelve months is $-0.43.
- Where does Castle Biosciences's income statement data come from?
- Every line is extracted from Castle Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
